Daclizumab - AbbVie/Biogen

Drug Profile

Daclizumab - AbbVie/Biogen

Alternative Names: BIIB-019; DAC HYP; Dacliximab; Daclizumab high-yield process; Daclizumab HYP; HAT antibody; Humanised anti-Tac antibody; R35; RO 247375; SMART anti-Tac antibody; Zenapax; Zinbryta

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Biogen; Dana-Farber Cancer Institute; National Cancer Institute (USA); PDL BioPharma
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase III Multiple sclerosis
  • Discontinued Asthma; Graft-versus-host disease; Haematological malignancies; Immune-mediated uveitis; Liver transplant rejection; Psoriasis; Tropical spastic paraparesis; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Apr 2018 Biogen has patent protection for daclizumab in USA and Europe
  • 02 Mar 2018 Withdrawn for Multiple sclerosis (Recurrent) in Ireland, United Kingdom, USA, Liechtenstein, Switzerland, Iceland, Australia, Canada, Norway, Liechtenstein (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top